|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xiong X, Zheng LW, Ding Y, Chen YF, Cai
YW, Wang LP, Huang L, Liu CC, Shao ZM and Yu KD: Breast cancer:
Pathogenesis and treatments. Signal Transduct Target Ther.
10(49)2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gradishar WJ: Cancer Treatment and
Research In: Optimizing Breast Cancer Management. Vol 173.
Springer, Cham, 2018.
|
|
4
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shahrokni A, Wu AJ, Carter J and Lichtman
SM: Long-term toxicity of cancer treatment in older patients. Clin
Geriatr Med. 32:63–80. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Nattenmüller CJ, Kriegsmann M, Sookthai D,
Fortner RT, Steffen A, Walter B, Johnson T, Kneisel J, Katzke V,
Bergmann M, et al: Obesity as risk factor for subtypes of breast
cancer: Results from a prospective cohort study. BMC Cancer.
18(616)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pontillo M, Trio R, Rocco N, Cinquerrui A,
Di Lorenzo M, Catanuto G, Magnoni F, Calenda F, Castiello CLJ,
Ingenito M, et al: Dietary interventions for breast cancer
prevention: Exploring the role of nutrition in primary and tertiary
prevention strategies. Healthcare (Basel). 13(407)2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rana A, Samtiya M, Dhewa T, Mishra V and
Aluko RE: Health benefits of polyphenols: A concise review. J Food
Biochem. 46(e14264)2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
de Carvalho JTG, Da Silva Baldivia D, de
Castro DTH, dos Santos HF, dos Santos CM, Oliveira AS, Alfredo TM,
Vilharva KN, de Picoli Souza K and Dos Santos EL: The
immunoregulatory function of polyphenols: Implications in cancer
immunity. J Nutr Biochem. 85(108428)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Erbas O: Cancer and Immunosuppression. J
Exp Bas Sci. 2:116–121. 2021.
|
|
11
|
Bayraktar S: Immunotherapy in Breast
Cancer. J Carcinog. 18(2)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gasparri ML, Ruscito I, Taghavi K, Farooqi
AA, Papadia A, Focaccetti C, Barnaba V, Panici PB and Mueller MD:
The Immunobiology of cancer: From Tumor Escape to Cancer
Immunoediting Towards Immunotherapy in Gynecologic Oncology.
Molecular Oncology: Underlying Mechanisms and Translational
Advancements, pp193-202, 2017.
|
|
13
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Swann JB and Smyth MJ: Immune surveillance
of tumors. J Clin Invest. 117:1137–1146. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rezaei N: Cancer immunology: A
Translational Medicine Context, Second edition, Springer Nature,
pp1-802, 2020.
|
|
16
|
Moura T, Laranjeira P, Caramelo O, Gil AM
and Paiva A: Breast cancer and tumor microenvironment: The crucial
role of immune cells. Curr Oncol. 32(143)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhou J, Tang Z, Gao S, Li C, Feng Y and
Zhou X: Tumor-associated macrophages: Recent insights and
therapies. Front Oncol. 10(188)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X,
Zhang B, Li Y, Liu B, Xia L and Huang W: Myeloid-derived suppressor
cells in cancer: Therapeutic targets to overcome tumor immune
evasion. Exp Hematol Oncol. 13(39)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Martinez LM, Robila V, Clark NM, Du W,
Idowu MO, Rutkowski MR and Bos PD: Regulatory T cells control the
switch from in situ to invasive breast cancer. Front Immunol.
10(1942)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Huang P, Zhou X, Zheng M, Yu Y, Jin G and
Zhang S: Regulatory T cells are associated with the tumor immune
microenvironment and immunotherapy response in triple-negative
breast cancer. Front Immunol. 14(1263537)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang F, Qi X, Wang X, Wei D, Wu J, Feng
L, Cai H, Wang Y, Zeng N, Xu T, et al: Structural basis of the
therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget.
8:90215–90224. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schmid P, Adams S, Rugo HS, Schneeweiss A,
Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, et al:
Atezolizumab and Nab-paclitaxel in advanced triple-negative breast
cancer. N Engl J Med. 379:2108–2121. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Keenan TE and Tolaney SM: Role of
immunotherapy in triple-negative breast cancer. J Natl Compr Canc
Netw. 18:479–489. 2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Santa-Maria CA, Kato T, Park JH, Kiyotani
K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, et
al: A pilot study of durvalumab and tremelimumab and immunogenomic
dynamics in metastatic breast cancer. Oncotarget. 9:18985–18996.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lembo RR, Manna L, Froechlich G, Sasso E,
Passariello M and De Lorenzo C: New insights on the role of
Anti-PD-L1 and Anti-CTLA-4 mAbs on different lymphocytes
subpopulations in TNBC. Cancers (Basel). 14(5289)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Selby MJ, Engelhardt JJ, Johnston RJ, Lu
L-S, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, et al:
Preclinical development of Ipilimumab and nivolumab combination
immunotherapy: Mouse tumor models, in vitro functional studies, and
cynomolgus macaque toxicology. PLoS One.
11(e0161779)2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yu S, Liu Q, Han X, Qin S, Zhao W, Li A
and Wu K: Development and clinical application of anti-HER2
monoclonal and bispecific antibodies for cancer treatment. Exp
Hematol Oncol. 6(31)2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Yang YH, Liu JW, Lu C and Wei JF: CAR-T
cell therapy for breast cancer: From basic research to clinical
application. Int J Biol Sci. 18:2609–2626. 2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Clifton GT, Gall V, Peoples GE and
Mittendorf EA: Clinical development of the E75 vaccine in breast
cancer. Breast Care. 11:116–121. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hoteit M, Oneissi Z, Reda R, Wakim F,
Zaidan A, Farran M, Abi-Khalil E and El-Sibai M: Cancer
immunotherapy: A comprehensive appraisal of its modes of
application. Oncol Lett. 22(655)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mina LA, Lim S, Bahadur SW and Firoz AT:
Immunotherapy for the treatment of breast cancer: Emerging new
data. Breast Cancer (Dove Med Press). 11:321–328. 2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
de la Cruz-Merino L, Chiesa M, Caballero
R, Rojo F, Palazón N, Carrasco FH and Sánchez-Margalet V: Breast
cancer immunology and immunotherapy: Current status and future
perspectives. Int Rev Cell Mol Biol. 331:1–53. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sugie T: Immunotherapy for metastatic
breast cancer. Chin Clin Oncol. 7(28)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Arimoto K, Miyauchi S, Liu M and Zhang DE:
Emerging role of immunogenic cell death in cancer immunotherapy.
Front Immunol. 15(1390263)2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Choi M, Shin J, Lee CE, Chung JY, Kim M,
Yan X, Yang WH and Cha JH: Immunogenic cell death in cancer
immunotherapy. BMB Rep. 56:275–286. 2023.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Galluzzi L, Vitale I, Warren S, Adjemian
S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch
E, et al: Consensus guidelines for the definition, detection and
interpretation of immunogenic cell death. J Immunother Cancer.
8(e000337)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fucikova J, Kepp O, Kasikova L, Petroni G,
Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G and Galluzzi L:
Detection of immunogenic cell death and its relevance for cancer
therapy. Cell Death Dis. 11(1013)2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Di Lorenzo C, Colombo F, Biella S,
Stockley C and Restani P: Polyphenols and human health: The role of
bioavailability. Nutrients. 13:1–30. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cháirez-Ramírez MH, de la Cruz-López KG
and García-Carrancá A: Polyphenols as antitumor agents targeting
key players in cancer-driving signaling pathways. Front Pharmacol.
12(710304)2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Coombs MRP, Harrison ME and Hoskin DW:
Apigenin inhibits the inducible expression of programmed death
ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett.
380:424–433. 2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kongtawelert P, Wudtiwai B, Shwe TH,
Pothacharoen P and Phitak T: Inhibitory effect of hesperidin on the
expression of programmed death ligand (PD-L1) in breast cancer.
Molecules. 25(252)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zeng A, Yu X, Chen B, Hao L, Chen P, Chen
X, Tian Y, Zeng J, Hua H, Dai Y and Zhao J: Tetrahydrocurcumin
regulates the tumor immune microenvironment to inhibit breast
cancer proliferation and metastasis via the CYP1A1/NF-κB signaling
pathway. Cancer Cell Int. 23(12)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
EFSA Panel on Nutrition, Novel Foods and
Food Allergens (NDA). Turck D, Bohn T, Castenmiller J, De Henauw S,
Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, et al: Safety
of tetrahydrocurcuminoids from turmeric (Curcuma longa L) as
a novel food pursuant to regulation (EU) 2015/2283. EFSA J.
19(e06936)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu M, Li C, Qu J, Sun S, Zhao Z, Wang W,
Lv W, Zhang Y, Cai Y, Zhao F, et al: Baicalein enhances immune
response in TNBC by inhibiting leptin expression of adipocytes.
Cancer Sci. 114:3834–3847. 2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Deng B, Yang B, Chen J, Wang S, Zhang W,
Guo Y, Han Y, Li H, Dang Y, Yuan Y, et al: Gallic acid induces
T-helper-1-like Treg cells and strengthens immune
checkpoint blockade efficacy. J Immunother Cancer.
10(e004037)2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang X, Cook KL, Warri A, Cruz IM, Rosim
M, Riskin J, Helferich W, Doerge D, Clarke R and Hilakivi-Clarke L:
Lifetime Genistein intake increases the response of mammary tumors
to tamoxifen in rats. Clin Cancer Res. 23:814–824. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Andrade F de O, Liu F, Zhang X, Rosim MP,
Dani C, Cruz I, Cruz I, Wang TTY, Helferich W, Li RW and
Hilakivi-Clarke L: Genistein reduces the risk of local mammary
cancer recurrence and ameliorates alterations in the gut microbiota
in the offspring of obese dams. Nutrients. 13(201)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Oršolić N, Kunštić M, Kukolj M, Gračan R
and Nemrava J: Oxidative stress, polarization of macrophages and
tumour angiogenesis: Efficacy of caffeic acid. Chem Biol Interact.
256:111–124. 2016.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Xie C, Chan L, Pang Y, Shang Y, Cao W,
Tuohan M, Deng Q, Wang Y, Zhao L and Wang W: Caffeic acid inhibits
the tumorigenicity of triple-negative breast cancer cells through
the FOXO1/FIS pathway. Biomed Pharmacother.
178(117158)2024.PubMed/NCBI View Article : Google Scholar
|
|
50
|
He S, Wang S, Liu S, Li Z, Liu X and Wu J:
Baicalein potentiated M1 macrophage polarization in cancer through
targeting PI3Kγ/NF-κB signaling. Front Pharmacol.
12(743837)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Song H, Jung JI, Cho HJ, Her S, Kwon SH,
Yu R, Kang YH, Lee KW and Park JH: Inhibition of tumor progression
by oral piceatannol in mouse 4T1 mammary cancer is associated with
decreased angiogenesis and macrophage infiltration. J Nutr Biochem.
26:1368–1378. 2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhu M, Tang X, Zhu Z, Gong Z, Tang W, Hu
Y, Hu Y, Cheng C, Wang H, Sarwar A, et al: STING activation in
macrophages by vanillic acid exhibits antineoplastic potential.
Biochem Pharmacol. 213(115618)2023.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang Y and Minden A: Current molecular
combination therapies used for the treatment of breast cancer. Int
J Mol Sci. 23(11046)2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Zeng A, Liang X, Zhu S, Liu C, Wang S,
Zhang Q, Zhao J and Song L: Chlorogenic acid induces apoptosis,
inhibits metastasis and improves antitumor immunity in breast
cancer via the NF-κB signaling pathway. Oncol Rep. 45:717–727.
2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Lin X, Dong Y, Gu Y, Kapoor A, Peng J, Su
Y, Wei F, Wang Y, Yang C, Gill A, et al: Taxifolin inhibits breast
cancer growth by facilitating CD8+ T cell infiltration and inducing
a novel set of genes including potential tumor suppressor genes in
1q213. Cancers (Basel). 15(3203)2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Qiu D, Yan X, Xiao X, Zhang G, Wang Y, Cao
J, Ma R, Hong S and Ma M: To explore immune synergistic function of
Quercetin in inhibiting breast cancer cells. Cancer Cell Int.
21(632)2021.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Song X and Li J: Screening of
Immune-related genes and predicting the immunotherapeutic effects
of formononetin in breast cancer: A bioinformatics analysis. Evid
Based Complement Alternat Med. 2022(9942373)2022.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Du G, Lin H, Yang Y, Zhang S, Wu X, Wang
M, Ji L, Lu L, Yu L and Han G: Dietary quercetin combining
intratumoral doxorubicin injection synergistically induces
rejection of established breast cancer in mice. Int
Immunopharmacol. 10:819–826. 2010.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Qin L, Jin L, Lu L, Lu X, Zhang C, Zhang F
and Liang W: Naringenin reduces lung metastasis in a breast cancer
resection model. Protein Cell. 2:507–516. 2011.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Huang X, Wu H, Wu X, Su W and Li P:
Naringenin/naringin therapeutic effects and the role of intestinal
microflora in them. Pharmacol Res. 219(107871)2025.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Rebello CJ, Beyl RA, Lertora JJL, Greenway
FL, Ravussin E, Ribnicky DM, Poulev A, Kennedy BJ, Castro HF,
Campagna SR, et al: Safety and pharmacokinetics of naringenin: A
randomized, controlled, single-ascending-dose clinical trial.
Diabetes Obes Metab. 22:91–98. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lee-Chang C, Bodogai M, Martin-Montalvo A,
Wejksza K, Sanghvi M, Moaddel R, de Cabo R and Biragyn A:
Inhibition of breast cancer metastasis by resveratrol-mediated
inactivation of tumor-evoked regulatory B cells. J Immunol.
191:4141–4151. 2013.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Zhang C, Liao Y, Li T, Zhong H, Shan L, Yu
P, Xia C and Xu L: Apigenin promotes apoptosis of 4T1 cells through
PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in
vivo. Toxicol Res (Camb). 13(tfae011)2024.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Nie L, Cai SY, Shao JZ and Chen J:
Toll-like receptors, associated biological roles, and signaling
networks in non-mammals. Front Immunol. 9(1523)2018.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Zhou J, Zhang L, Liu S, DeRubeis D and
Zhang D: Toll-like receptors in breast cancer immunity and
immunotherapy. Front Immunol. 15(1418025)2024.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Chang H, Wang Y, Yin X, Liu X and Xuan H:
Ethanol extract of propolis and its constituent caffeic acid
phenethyl ester inhibit breast cancer cells proliferation in
inflammatory microenvironment by inhibiting TLR4 signal pathway and
inducing apoptosis and autophagy. BMC Complement Altern Med.
17(471)2017.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pan J, Shen J, Si W, Du C, Chen D, Xu L,
Yao M, Fu P and Fan W: Resveratrol promotes MICA/B expression and
natural killer cell lysis of breast cancer cells by suppressing
c-Myc/miR-17 pathway. Oncotarget. 8:65743–65758. 2017.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Ding B, Li J, Yan JL, Jiang CY, Qian LB
and Pan J: Resveratrol contributes to NK cell-mediated breast
cancer cytotoxicity by upregulating ULBP2 through miR-17-5p
downmodulation and activation of MINK1/JNK/c-Jun signaling. Front
Immunol. 16(1515605)2025.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Li Q, Huyan T, Ye LJ, Li J, Shi JL and
Huang QS: Concentration-dependent biphasic effects of resveratrol
on human natural killer cells in vitro. J Agric Food Chem.
62:10928–10935. 2014.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Wang B, Xu H, Hu X, Ma W, Zhang J, Li Y,
Yu M, Zhang Y, Li X and Ye X: Synergetic inhibition of daidzein and
regular exercise on breast cancer in bearing-4T1 mice by regulating
NK cells and apoptosis pathway. Life Sci.
245(117387)2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Abdel-Latif M, Riad A, Soliman RA,
Elkhouly AM, Nafae H, Gad MZ, Motaal AA and Youness RA:
MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated
quercitin glycoside alters immunogenic and oncogenic profiles of
breast cancer. Mol Cell Biochem. 477:1281–1293. 2022.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Liu H, Wang Z, Zhou Y and Yang Y: MDSCs in
breast cancer: An important enabler of tumor progression and an
emerging therapeutic target. Front Immunol.
14(1199273)2023.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Wang Q, Yang B, Wang N and Gu J: Tumor
immunomodulatory effects of polyphenols. Front Immunol.
13(1041138)2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Forghani P, Khorramizadeh MR and Waller
EK: Silibinin inhibits accumulation of myeloid-derived suppressor
cells and tumor growth of murine breast cancer. Cancer Med.
3:215–224. 2014.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Weber R, Fleming V, Hu X, Nagibin V, Groth
C, Altevogt P, Utikal J and Umansky V: Myeloid-derived suppressor
cells hinder the anti-cancer activity of immune checkpoint
inhibitors. Front Immunol. 9(1310)2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Xu P, Yan F, Zhao Y, Chen X, Sun S, Wang Y
and Ying L: Green Tea Polyphenol EGCG attenuates MDSCs-mediated
Immunosuppression through Canonical and Non-canonical pathways in a
4T1 murine breast cancer model. Nutrients. 12(1042)2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Hu J, Webster D, Cao J and Shao A: The
safety of green tea and green tea extract consumption in
adults-Results of a systematic review. Regul Toxicol Pharmacol.
95:412–433. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Del Prete A, Salvi V, Soriani A,
Laffranchi M, Sozio F, Bosisio D and Sozzani S: Dendritic cell
subsets in cancer immunity and tumor antigen sensing. Cell Mol
Immunol. 20:432–447. 2023.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Xiong H, Chen Z, Lin B, Xie B, Liu X, Chen
C, Li Z, Jia Y, Wu Z, Yang M, et al: Naringenin regulates
FKBP4/NR3C1/NRF2 axis in autophagy and proliferation of breast
cancer and differentiation and maturation of dendritic cell. Front
Immunol. 12(745111)2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Singh V, Ubaid S, Kashif M, Singh T, Singh
G, Pahwa R and Singh A: Role of inflammasomes in cancer immunity:
Mechanisms and therapeutic potential. J Exp Clin Cancer Res.
44(109)2025.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Khan MI, Mohammad Nur S and Abdulaal WH: A
study on DNA methylation modifying natural compounds identified
EGCG for induction of IFI16 gene expression related to the innate
immune response in cancer cells. Oncol Lett. 24(218)2022.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Tabrez S, Jabir NR, Adhami VM, Khan MI,
Moulay M, Kamal MA and Mukhtar H: Nanoencapsulated dietary
polyphenols for cancer prevention and treatment: Successes and
challenges. Nanomedicine. 15:1147–1162. 2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Shiri S, Alizadeh AM, Baradaran B,
Farhanghi B, Shanehbandi D, Khodayari S, Khodayari H and Tavassoli
A: Dendrosomal curcumin suppresses metastatic breast cancer in mice
by changing M1/M2 macrophage balance in the tumor microenvironment.
Asian Pac J Cancer Prev. 16:3917–3922. 2015.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Zheng F, Luo Y, Liu Y, Gao Y, Chen W and
Wei K: Nano-baicalein facilitates chemotherapy in breast cancer by
targeting tumor microenvironment. Int J Pharm.
635(122778)2023.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Youssry SA, El-Sheredy HG and Shalaby TI:
In vitro evaluation of antitumor and immunomodulatory potential of
Curcumin Nano-emulsion on breast cancer. Bionanoscience.
12:841–850. 2022.
|
|
86
|
Barahuie F, Dorniani D, Saifullah B,
Arulselvan P, Hussein MZ, Jaganathan R, Amin El-Fagaih FM and
Pratiwi AR: Impacts of designed vanillic acid-polymer-magnetic iron
oxide nanocomposite on breast cancer cells. Heliyon.
10(e32863)2024.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Harini G, Shree Ganesh S, Anushikaa R,
Bharathi R, Aravind S, Vatsala K, Shanmugavadivu A and Selvamurugan
N: Antiproliferative and apoptotic effects of pH-responsive
veratric acid-loaded polydopamine nanoparticles in human triple
negative breast cancer cells. Chem Biodivers.
20(e202201006)2023.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Safwat S, Ishak RAH, Hathout RM and
Mortada ND: Bioinspired caffeic acid-laden milk protein-based
nanoparticles targeting folate receptors for breast cancer
treatment. Ther Deliv. 16:43–61. 2025.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Sarnaik S, Ahmed H, Hussain N, Kundu S,
Sahu BD and Alexander A: Folic acid-chitosan conjugated mesoporous
silica nanoparticles for enhanced piceatannol uptake in MCF-7
breast cancer cells. ACS Omega. 10:45417–47437. 2025.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Zhang X, Fei G, Xiujia S, Ganesan K and
Chen J: Natural compound-nanoparticle therapies for breast cancer:
A review from 2018-2025. Phytomedicine. 150(157652)2026.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Zhu Q, Zhang R, Zhao Z, Xie T and Sui X:
Harnessing phytochemicals: Innovative strategies to enhance cancer
immunotherapy. Drug Resist Updat. 79(101206)2025.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Meng M, Wu J, Feng Y, Lin L, Chen J, Pang
X, Li Y, Hao K, Tian H and Chen X: A comprehensive strategy based
on high clinical translational nanosystem for programmable
immunotherapy of triple negative breast cancer. Adv Mater.
36(e2314309)2024.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Li C, Xu Y, Zhang J, Zhang Y, He W, Ju J,
Wu Y and Wang Y: The effect of resveratrol, curcumin and quercetin
combination on immuno-suppression of tumor microenvironment for
breast tumor-bearing mice. Sci Rep. 13(13278)2023.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Zhu J, Lee H, Huang R, Zhou J, Zhang J,
Yang X, Zhou W, Jiang W and Chen S: Harnessing nanotechnology for
cancer treatment. Front Bioeng Biotechnol.
12(1514890)2025.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Lei C, Yao Y, Xie Q, Li N, Zhu C, Lan H,
Yang S, Wang G, Peng X, Zheng D, et al: Synergistic
immunomodulatory effects of naringenin and photothermal therapy in
triple-negative breast cancer. iScience. 28(114124)2025.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Hussein MA, Hamdy AM, Abdelrhman IG, Auf
M, Saifeldeen ER, Elashmony SM, Abuelkasem SS and Metwaly AM:
Grafting of resveratrol-chitosan nanoparticles as a promising
radiosensitizer and protector in DMBA-induced breast cancer in
mice. Curr Cancer Drug Targets: Sep 5, 2025 doi:
10.2174/0115680096364549250828062651 (Epub ahead of print).
|
|
97
|
Yang N, Fan Z, Zhu F, Li J, Wang Q, Xia G,
Yu S and Ding L: A resveratrol dimer nanoagent boosts
sonodynamic-immunotherapy via suprathreshold autophagy. J Control
Release. 394(114850)2026.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Zhang X, Tian W, Cai X, Wang X, Dang W,
Tang H, Cao H, Wang L and Chen T: Hydrazinocurcumin Encapsuled
nanoparticles ‘Re-Educate’ tumor-associated macrophages and exhibit
anti-tumor effects on breast cancer following STAT3 suppression.
PLoS One. 8(e65896)2013.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Salemme V, Centonze G, Cavallo F,
Defilippi P and Conti L: The crosstalk between tumor cells and the
immune microenvironment in breast cancer: Implications for
immunotherapy. Front Oncol. 11(610303)2021.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Retecki K, Seweryn M, Graczyk-Jarzynka A
and Bajor M: The immune landscape of breast cancer: Strategies for
overcoming immunotherapy resistance. Cancers (Basel).
13(6012)2021.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Rai A, Deshpande SG, Vaidya A and Shinde
RK: Advancements in immunotherapy for breast cancer: Mechanisms,
efficacy, and future directions. Cureus. 16(e68351)2024.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Golonko A, Pienkowski T, Swislocka R,
Orzechowska S, Marszalek K, Szczerbinski L, Swiergiel AH and
Lewandowski W: Dietary factors and their influence on immunotherapy
strategies in oncology: A comprehensive review. Cell Death Dis.
15(254)2024.PubMed/NCBI View Article : Google Scholar
|
